Meeting
2020 ASCO Virtual Scientific Program
Outcomes of Lynch syndrome (LS) patients treated with immune checkpoint inhibitors (ICI).
Authors
Shahla Bari
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Shahla Bari , Richard D. Kim , Xia Wang , Marco Matejcic , Jameel Muzaffar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Cancer Prevention, Risk Reduction, and Genetics
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Cancer Genetics
Citation
J Clin Oncol 38: 2020 (suppl; abstr 1548)
DOI
10.1200/JCO.2020.38.15_suppl.1548
Abstract #
1548
Poster Bd #
40
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Outcomes with immunotherapy between Lynch syndrome vs non-Lynch syndrome microsatellite instability-high colorectal cancer.
First Author: Cody Eslinger
Poster
2023 ASCO Annual Meeting
A pan-cancer statistical study of microsatellite instability and Lynch syndrome–associated mismatch repair genes germline mutations.
First Author: Huiya Cao
Poster
2023 ASCO Annual Meeting
Clinical and molecular characterization of microsatellite stable (MSS) tumors in patients with Lynch syndrome (LS).
First Author: Emily Harrold
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in >28,000 colorectal tumors.
First Author: Rouba Ali-Fehmi